Targeting Collagen Pathways as an HFpEF Therapeutic Strategy
Authors:
- Alice BonanniABAlice Bonanni
- Ramona VinciRVRamona Vinci
- Alessia D’aielloADAlessia D’aiello
- Maria Chiara GrimaldiMGMaria Chiara Grimaldi
- Marianna Di SarioMSMarianna Di Sario
- Dalila TarquiniDTDalila Tarquini
- Luca ProtoLPLuca Proto
- Anna SeverinoASAnna Severino
- Daniela PedicinoDPDaniela Pedicino
- Giovanna LiuzzoGLGiovanna Liuzzo
Open Access
- 9 September 2023
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (18) , 5862
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a complex and heterogeneous clinical syndrome. The prevalence is expected to increase in the coming years, resulting in heart failure with reduced ejection fraction (HFrEF). This condition poses a burden to the global health care system as the number of patients affected by this condition is constantly increasing due to a rising average lifespan. The absence of validated drugs effective in reducing hospitalization rates and mortality may reflect the impossibility of applying a one size fits all approach as in HFrEF, heading for a personalized approach. Available evidence demonstrated the link between collagen quantity and quality alterations, and cardiac remodeling. In the context of fibrosis, collagen cross-linking is strictly involved, displaying two types of mechanisms: enzymatic and non-enzymatic. In the murine model, enzymatic inhibition of fibrosis-inducing protease-activated receptor-1 (PAR1) and transforming growth factor (TGF)-β signaling appeared to reduce cardiac fibrosis. On the other hand, in the case of non-enzymatic cross-linking, sodium glucose co-transporter type 2 inhibitors (SGLT2is), appeared to counteract the deposition of advanced glycation end-products (AGEs), which in turn contributed to ventricular remodeling. In this review, we address the mechanisms associated with collagen alterations to identify potential targets of cardiac fibrosis in HFpEF patients.Keywords
Funding Information
- Italian Ministry of Health—Ricerca Corrente
This publication has 54 references indexed in Scilit:
- Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart diseaseFibrogenesis & Tissue Repair, 2012
- Effects of Prolonged-Release Torasemide Versus Furosemide on Myocardial Fibrosis in Hypertensive Patients with Chronic Heart Failure: A Randomized, Blinded–End Point, Active-Controlled StudyClinical Therapeutics, 2011
- The Collagen FamilyCold Spring Harbor Perspectives in Biology, 2010
- Stiffening of Human Skin Fibroblasts with AgeBiophysical Journal, 2010
- Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspectsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Effects of Age on Plasma Matrix Metalloproteinases (MMPs) and Tissue Inhibitor of Metalloproteinases (TIMPs)Journal of Cardiac Failure, 2007
- Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast functionCardiovascular Research, 2005
- Reduction of the Accumulation of Advanced Glycation End Products by ACE Inhibition in Experimental Diabetic NephropathyDiabetes, 2002
- Angiogenesis induced by advanced glycation end products and its prevention by cerivastatinThe FASEB Journal, 2002
- Type I and III collagen content and fibre distribution in normal human skin during ageingBritish Journal of Dermatology, 1987